Thyrocare Technologies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹271 Cr +24.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
TT

Thyrocare Technologies Ltd

Q1 FY27

Thyrocare Technologies Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹240Cr
+24.4% YoY
+7.1% QoQ
Net profit
₹51Cr
+34.2% YoY
+4.1% QoQ
Margin
32%
+2 pp YoY
−2 pp QoQ

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Price₹485
Market cap₹7.7K Cr
P/E42.7

The short version

Franchisee additions guidance for FY27: 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4; net additions may be lower due to churn. Thyrocare targets mid- to high-teens percentage growth in franchisee additions for FY27, indicating steady volume growth potential.

From Thyrocare Technologies Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • Franchisee additions guidance for FY27: 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4; net additions may be lower due to churn.
  • Medium-term specialty segment (genomics, allergy) expected to form 15-20% of portfolio within 3-5 years.
  • Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth.
  • Revenue growth target for the company is conservatively around mid to high teens percentage annually.
  • New franchisee additions and field force expansions to support volume growth and market penetration in Tier 3 and 4 cities.
  • Emphasis on higher-value, semi-specialized tests expected to improve realization and margins.

2 more points from Thyrocare Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Most investments in specialty diagnostics have already been made, focusing on central labs in Mumbai and Delhi.
  • Future capex on specialty testing is expected to be limited, mostly expansion CAPEX if volumes exceed expectations.
  • No significant capex anticipated for specialty segment in the next year.

2 more points from Thyrocare Technologies Ltd's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Thyrocare Technologies Ltd Q1 FY27 results — key figures

Thyrocare Technologies Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue240193+24.4%224+7.1%
Operating profit (EBITDA)7758+32.8%75+2.7%
Operating margin32%30%+2 pp34%-2 pp
Profit before tax6850+36%64+6.3%
Net profit (PAT)5138+34.2%49+4.1%
EPS (₹)3.282.45+33.9%2.96+10.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Aatmaj Health (Q1 FY27)

    Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again

  • Asarfi Hospital (Q1 FY27)

    Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q

  • KMC Speciality (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • 3B Blackbio (Q1 FY27)

    Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q1 FY27 results?

Franchisee additions guidance for FY27: 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4; net additions may be lower due to churn. Thyrocare targets mid- to high-teens percentage growth in franchisee additions for FY27, indicating steady volume growth potential.

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 42.7 with a market cap of ₹7,723 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

Most investments in specialty diagnostics have already been made, focusing on central labs in Mumbai and Delhi.

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.